(R)-2-((tert-Butoxycarbonyl)amino)-3-(o-tolyl)propanoic acid, 95.0%, 10g

5-Bromo-6-hydroxypicolinic acid, 95.0%, 25g

2-Bromo-4-methoxybenzoic acid, 98.0%, 10g

N,N-dibutyl-4-(7-ethyl-3-(2-fluorophenyl)-3,7-dihydropyrano[2,3-c]carbazol-3-yl)aniline, 95+%, 250mg

(R,S)-tert-Butyl 3-methyl-4-oxopiperidine-1-carboxylate, 95.0%, 25g

2-Cyclobutyl-2-phenylacetic acid, 98%, 5g

Glass syringe with Luer connection (glass), 30 ml, 1 piece

1-(6-Bromo-2-pyridinyl)-4-piperidinecarboxylic acid, 1g

METHYL 2-(1H-PYRROLO[2,3-B]PYRIDIN-5-YLOXY)-4-FLUOROBENZOATE, 97.0%, 50g

5-Bromo-2-nitrobenzotrifluoride, 98.0%, 100g

(2S,5R)-6-(Benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide, 97%, 1g

1-(2,5-Dihydro-1H-pyrrol-1-yl)-2,2-dimethylpropan-1-one, 97%, 100mg

(2,2'-Bipyridine)bis[2-(2,4-difluorophenyl)pyridine]iridium(III) Hexafluorophosphate>80.0%(HPLC)200mg